
February 6, 2024
RegMed Investors’ (RMi) pre-open: sector’s investors are conflicted as share pricing declines contaminate potential buy attitude
February 5, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector passes more gas
February 5, 2024
RegMed Investors (RMi): Adverum Biotechnologies (ADVM) 106.25 M Share Private Placement priced at $1.20
February 5, 2024
RegMed Investors’ (RMi) pre-open: the “canary in the (sectors) coal mine”
February 2, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector fluctuates what’s different?
February 2, 2024
RegMed Investors’ (RMi) pre-open: what goes round, sometimes comes back to bite
February 1, 2024
RegMed Investors (RMi) Closing Bell: back on the roller-coaster
February 1, 2024
RegMed Investors’ (RMi) pre-open: a stunned sector with a time to nibble at bottoms
January 31, 2024
RegMed Investors (RMi) Closing Bell: When you are a cell and gene therapy believer, the benefit of the doubt is immeasurable – the sector is oversold
January 31, 2024
RegMed Investors’ (RMi) pre-open: perspective draws on a weak pre and aftermarket
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors